LIXT News and Press, Lixte Biotechnology Holdings Inc. From 08/13/25

2025-08-13 14:33:21 ET DENVER, Colo., Aug 13, 2025 ( 247marketnews.com )- Markets are pulsing with momentum heading into the final stretch of the trading day, with several names setting up for extended-session fireworks. Shares of Momentus (NASDAQ:MNTS) , today’s most act...

2025-08-13 09:43:26 ET DENVER, Colo., Aug 13, 2025 ( 247marketnews.com )- This morning’s market opens against a backdrop of aggressive capital allocation shifts, strategic crypto accumulation, and earnings momentum from players across biotech, Web3, media, and aerospace. As corpo...

DENVER, Aug. 13, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com , a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, reports that LIXTE Biotechnology Holdings (Nasdaq: LIXT), a clinical-stage pharmaceutical company developing bre...

PASADENA, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) ( Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that its Board of Directors has approved a strategic capital...

2025-07-16 08:34:00 ET More on Lixte Biotechnology Holdings, Inc. Lixte Biotechnology announces $5M equity financing; shares down Financial information for Lixte Biotechnology Holdings, Inc. Read the full article on Seeking Alpha For further details see: ...

PASADENA, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) ( Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it has received a letter from the Nasdaq Hearings Panel stat...

New York, NY, July 09, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the closing of a $1.5 million registered direct offering for Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT), in which it served as the exclusive placement ...

Article Indicates that Inhibition of PP2A Enhances Immunotherapy Response with LIXTE’s Proprietary Compound LB100 PASADENA, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) ( Nas...

PASADENA, CALIF, July 08, 2025 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the “Company”), a clinical stage pharmaceutical company, today announced the closing of a registered direct offering with accredited investors for the purchase and sale of approxi...

New York, NY, July 08, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the closing of a $5.0 million private placement for Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT), in which it served as the exclusive placement agent. ...